Twist Bioscience ( (TWST) ) has released its Q2 earnings. Here is a breakdown of the information Twist Bioscience presented to its investors.
Twist Bioscience Corporation, a mid-cap growth and value equity company in the life sciences segment of the healthcare sector, is known for its innovative silicon-based DNA synthesis platform that aids in precision and high-throughput synthesis, sequencing, and therapeutics discovery.
In its fiscal second quarter of 2025, Twist Bioscience reported record revenue of $92.8 million, marking a 23% increase from the previous year. The company also announced the spin-out of its DNA data storage application into a new entity, Atlas Data Storage, backed by significant investment from prominent venture partners.
Key financial highlights include a gross margin improvement to 49.6% from 41.0% year-over-year, and a reduction in net loss to $39.3 million from $45.5 million. The company also saw growth in its SynBio, NGS, and Biopharma revenue streams, with respective increases of 21%, 25%, and 21% compared to the same period last year.
Twist Bioscience’s strategic move to spin out Atlas Data Storage is aimed at focusing on DNA data storage advancements while maintaining its core business growth. The company anticipates achieving adjusted EBITDA breakeven by the end of fiscal 2026, reflecting a positive outlook on its financial trajectory.
Looking forward, Twist Bioscience expects continued revenue growth in fiscal 2025, with projections between $372 million to $379 million, and aims to exceed a 50% gross margin by the fourth quarter, indicating a strong commitment to enhancing profitability and market presence.